Preoperative Neutrophil-to-Lymphocyte Ratio Predicts Recurrence in HPV-Associated Oropharyngeal Cancer After Transoral Robotic Surgery.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 42371658.
- Also identified by DOI 10.1002/ohn.70328.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Evaluate the role of preoperative neutrophil-to-lymphocyte ratio (NLR) as a predictor of survival outcomes after transoral robotic surgery (TORS) for human papillomavirus-related (HPV+) oropharyngeal squamous cell carcinoma (OPSCC). Single-institution retrospective review of patients who underwent TORS for HPV + OPSCC from April 2014 to October 2021 and had a preoperative complete blood count test. Tertiary academic center. Preoperative NLR was calculated from complete blood counts drawn within 1 month prior to surgery. Receiver operating characteristic curves evaluated performance of prognostic markers. Kaplan-Meier estimator and Cox regression analyses were used to evaluate survival outcomes when controlling for confounding variables. A total of 117 patients were included (85.5% male, 94.0% Caucasian, 59.6 ± 9.1 years old), of which 13 patients (11.1%) recurred at a median of 23.5 ± 23 months, including 7 distant metastases. At the latest follow-up, 90.6% remained alive. On Kaplan-Meier analyses, a preoperative NLR of >2.2 was associated with worse recurrence-free survival (77.1% vs 95.5%, P = .02), whereas overall survival was similar between patients (P = .94). When controlling for demographics, tumor stage, pathologic risk criteria, and adjuvant therapy, NLR > 2.2 remained a significant independent predictor of recurrence on multivariate Cox regression analysis (HR 20.6, 95% CI 1.92-80.7, P = .012). While OS was similar across groups, a preoperative NLR of >2.2 predicted worse recurrence-free survival in a cohort of patients with HPV + OPSCC who underwent TORS. Future studies may consider integrating NLR into prospective trials as a complementary risk-stratification biomarker.